Published in BMJ on October 26, 2002
Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol (2000) 2.71
Toll of allergy reduced by probiotics. Lancet (2001) 1.54
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22
New treatments for atopic dermatitis. BMJ (2002) 1.11
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol (2001) 1.07
Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci (2003) 2.94
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev (2005) 2.42
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol (2006) 2.00
Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. J Am Acad Dermatol (2009) 1.85
The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med (2010) 1.70
Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol (2003) 1.68
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol (2011) 1.60
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol (2009) 1.55
Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol (2004) 1.52
Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol (2007) 1.46
Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res (2006) 1.42
FK506 controls CD40L-induced systemic autoimmunity in mice. J Invest Dermatol (2006) 1.42
Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol (2006) 1.41
Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol (2003) 1.33
Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.27
alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem (2004) 1.26
Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One (2010) 1.24
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J Invest Dermatol (2005) 1.16
Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol (2002) 1.12
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol (2004) 1.11
Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology (2009) 1.10
Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol (2007) 1.07
alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum (2009) 1.06
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol (2006) 1.06
Successful treatment of generalized eruptive histiocytoma with PUVA. J Dtsch Dermatol Ges (2007) 1.05
Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem (2009) 1.04
Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab (2008) 1.02
Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem (2003) 1.02
Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol (2009) 1.00
Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann Neurol (2014) 0.97
Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol (2002) 0.97
Immune response modifiers--mode of action. Exp Dermatol (2006) 0.97
Role of vasculature in atopic dermatitis. J Allergy Clin Immunol (2006) 0.96
Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol (2006) 0.94
[Current situation of dermatologic surgery in Germany]. J Dtsch Dermatol Ges (2006) 0.94
Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol (2007) 0.94
Neutral endopeptidase and angiotensin-converting enzyme -- key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol (2004) 0.93
α-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. J Invest Dermatol (2012) 0.93
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. PLoS One (2010) 0.92
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis (2008) 0.91
Solar-simulated ultraviolet radiation-induced upregulation of the melanocortin-1 receptor, proopiomelanocortin, and alpha-melanocyte-stimulating hormone in human epidermis in vivo. J Invest Dermatol (2004) 0.91
Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulating hormone in human dermal papilla cells. Endocrinology (2005) 0.91
Chronic pruritus: targets, mechanisms and future therapies. Drug News Perspect (2008) 0.90
Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol (2009) 0.90
Successful treatment of palmoplantar hyperkeratotic psoriasis with a combination of etanercept and alitretinoin. J Clin Aesthet Dermatol (2011) 0.90
The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components. Arthritis Rheum (2009) 0.89
Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol (2010) 0.89
Pathogenesis of pruritus. J Dtsch Dermatol Ges (2011) 0.89
MRSA eradication in dermatologic outpatients - theory and practice. J Dtsch Dermatol Ges (2011) 0.88
Melanocortins in fibroblast biology--current update and future perspective for dermatology. Exp Dermatol (2004) 0.86
Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol (2010) 0.86
Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol (2011) 0.85
The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol (2003) 0.84
KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signaling in human sebocytes. J Immunol (2010) 0.83
An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology (2007) 0.83
Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol (2007) 0.83
Dermatomyositis associated with malignant melanoma--a marker of poor prognosis? J Am Acad Dermatol (2006) 0.83
Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol (2003) 0.81
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol (2008) 0.81
Putative neuronal mechanisms of sensitive skin. Exp Dermatol (2009) 0.81
L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARalpha-independent expression. Int J Biochem Cell Biol (2004) 0.81
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol (2011) 0.81
Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol (2004) 0.81
Itch in atopic dermatitis - pathophysiology and treatment. Acta Dermatovenerol Croat (2010) 0.80
Disseminated giant molluscum contagiosum in a patient with idiopathic CD4+ lymphocytopenia. Successful eradication with systemic interferon. Dermatology (2008) 0.80
Treatment of extra-abdominal aggressive fibromatosis with pegylated interferon. J Am Acad Dermatol (2008) 0.80
Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci (2010) 0.79
Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. Eur J Dermatol (2007) 0.79
Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol (2003) 0.79
Pathway management in ambulatory wound care: defining local standards for quality improvement and interprofessional care. Int Wound J (2005) 0.79
[Pruritus--pathophysiology, clinical features and therapy--an overview]. J Dtsch Dermatol Ges (2003) 0.78
Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology (2003) 0.78
Monitoring neuropeptide-specific proteases: processing of the proopiomelanocortin peptides adrenocorticotropin and alpha-melanocyte-stimulating hormone in the skin. Exp Dermatol (2006) 0.78
Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol (2008) 0.78
NK-1 Antagonists and Itch. Handb Exp Pharmacol (2015) 0.78
Modulation of basophil activity: a novel function of the neuropeptide α-melanocyte-stimulating hormone. J Allergy Clin Immunol (2011) 0.78
[Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine]. J Dtsch Dermatol Ges (2003) 0.78
Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J (2004) 0.78
The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. Am J Pathol (2011) 0.78
G-DRG Version 2009: new developments. J Dtsch Dermatol Ges (2009) 0.78
Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges (2008) 0.77
A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis. Dermatology (2009) 0.77
Pruritus in pregnancy and childhood--do we really consider all relevant differential diagnoses? Eur J Dermatol (2005) 0.77
Lichen planus responding to efalizumab. J Am Acad Dermatol (2007) 0.77
[Sunprotection: possibilities and limitations]. J Dtsch Dermatol Ges (2005) 0.77
Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag (2006) 0.77
Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges (2007) 0.77
Galectin-2 suppresses contact allergy by inducing apoptosis in activated CD8+ T cells. J Immunol (2009) 0.77
Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function. Exp Dermatol (2006) 0.77
Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model. Arthritis Rheum (2013) 0.76
Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol (2006) 0.76
[Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)]. J Dtsch Dermatol Ges (2005) 0.76
Atomic force microscopy as an innovative tool for nanoanalysis of native stratum corneum. Exp Dermatol (2006) 0.76
KU812 basophils express urocortin, CRH-R, MC1R and steroidogenic enzymes and secrete progesterone. Exp Dermatol (2012) 0.75
Terminating the stress: peripheral peptidolysis of proopiomelanocortin-derived regulatory hormones by the dermal microvascular endothelial cell extracellular peptidases neprilysin and angiotensin-converting enzyme. Endocrinology (2007) 0.75
Is MC1 dispensable for regulation of cutaneous inflammatory and immune responses? Exp Dermatol (2013) 0.75